Key facts
- It has raised $5.0M; the latest was Later Stage VC ($5.0M) in Apr 2026.
- Notable investors include 4YFN, Africa Health Ventures, Global Innovation Fund, SAB Foundation, Savant (South Africa) — 8 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 8 names
- ·Watchlist + deal alerts for AI Diagnostics (Decision/Risk Analysis)
- ·The full record, as it builds
Funding rounds
No funding rounds for AI Diagnostics (Decision/Risk Analysis) are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About AI Diagnostics (Decision/Risk Analysis)
Developer of an artificial intelligence-powered diagnostics platform designed for nurses to detect diseases early. The company's platform uses a digital stethoscope to analyze data from tuberculosis patients, identify potential health concerns, and provide instant results, enabling nurses to filter out TB-negative patients, curb the spread of the disease, boost treatment outcomes, and reduce patient suffering.
- Sector
- Healthcare
- HQ
- Cape Town, South Africa
- Founded
- 2020
- Employees
- 16
- Website
- aidiagnostics.health/
- Ownership
- Privately Held (backing)
AI Diagnostics (Decision/Risk Analysis) doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in AI Diagnostics (Decision/Risk Analysis) shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on AI Diagnostics (Decision/Risk Analysis) in its N-PORT filings yet. We sweep new filings monthly.